Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery

Bååth, Maria LU ; Westbom-Fremer, Sofia LU orcid ; Martin de la Fuente, Laura LU ; Ebbesson, Anna LU ; Davis, Juliette ; Malander, Susanne LU orcid ; Måsbäck, Anna LU ; Kannisto, Päivi LU and Hedenfalk, Ingrid LU orcid (2020) In Molecular and Cellular Oncology 7(6).
Abstract

The transcription factor SOX2 is a well-established and important stem cell marker. Its role in cancer biology remains unclear, but it has been proposed to also be a marker of cancer stem cells. We investigated the role of SOX2 protein expression in women with high-grade serous ovarian cancer (HGSOC) to determine its potential prognostic and treatment predictive value. We constructed a tissue microarray of 130 advanced stage HGSOC tumors with an average of 6 cores each, stained for SOX2 protein expression and evaluated survival outcomes. We also treated two HGSOC cell lines with carboplatin and paclitaxel and measured SOX2 expression by RT-PCR and immunoblotting at different doses and time-points. Among patients with non-radical... (More)

The transcription factor SOX2 is a well-established and important stem cell marker. Its role in cancer biology remains unclear, but it has been proposed to also be a marker of cancer stem cells. We investigated the role of SOX2 protein expression in women with high-grade serous ovarian cancer (HGSOC) to determine its potential prognostic and treatment predictive value. We constructed a tissue microarray of 130 advanced stage HGSOC tumors with an average of 6 cores each, stained for SOX2 protein expression and evaluated survival outcomes. We also treated two HGSOC cell lines with carboplatin and paclitaxel and measured SOX2 expression by RT-PCR and immunoblotting at different doses and time-points. Among patients with non-radical debulking surgery overall and progression-free survival were shorter for patients with SOX2 positive tumors (mean 26 vs. 39 months, log-rank test: p = .0076, and mean 14 vs. 19 months, p = .055, respectively). Knockdown of SOX2 in cell lines did not affect growth inhibition following chemotherapy treatment. Our results show that SOX2 has a strong prognostic potential among HGSOC patients with residual tumor tissue after debulking surgery and suggest that SOX2 expressing cells remaining after non-radical debulking surgery may constitute a subpopulation of cancer stem cells with greater tumor-initiating potential.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cancer stem cells, high-grade serous ovarian cancer, radical surgery, SOX2, survival
in
Molecular and Cellular Oncology
volume
7
issue
6
article number
1805094
publisher
Taylor & Francis
external identifiers
  • scopus:85090303239
  • pmid:33235906
ISSN
2372-3556
DOI
10.1080/23723556.2020.1805094
language
English
LU publication?
yes
id
22813360-b6ab-4a19-82b7-081ec74de802
date added to LUP
2020-09-15 12:29:47
date last changed
2024-05-29 19:47:03
@article{22813360-b6ab-4a19-82b7-081ec74de802,
  abstract     = {{<p>The transcription factor SOX2 is a well-established and important stem cell marker. Its role in cancer biology remains unclear, but it has been proposed to also be a marker of cancer stem cells. We investigated the role of SOX2 protein expression in women with high-grade serous ovarian cancer (HGSOC) to determine its potential prognostic and treatment predictive value. We constructed a tissue microarray of 130 advanced stage HGSOC tumors with an average of 6 cores each, stained for SOX2 protein expression and evaluated survival outcomes. We also treated two HGSOC cell lines with carboplatin and paclitaxel and measured SOX2 expression by RT-PCR and immunoblotting at different doses and time-points. Among patients with non-radical debulking surgery overall and progression-free survival were shorter for patients with SOX2 positive tumors (mean 26 vs. 39 months, log-rank test: p = .0076, and mean 14 vs. 19 months, p = .055, respectively). Knockdown of SOX2 in cell lines did not affect growth inhibition following chemotherapy treatment. Our results show that SOX2 has a strong prognostic potential among HGSOC patients with residual tumor tissue after debulking surgery and suggest that SOX2 expressing cells remaining after non-radical debulking surgery may constitute a subpopulation of cancer stem cells with greater tumor-initiating potential.</p>}},
  author       = {{Bååth, Maria and Westbom-Fremer, Sofia and Martin de la Fuente, Laura and Ebbesson, Anna and Davis, Juliette and Malander, Susanne and Måsbäck, Anna and Kannisto, Päivi and Hedenfalk, Ingrid}},
  issn         = {{2372-3556}},
  keywords     = {{Cancer stem cells; high-grade serous ovarian cancer; radical surgery; SOX2; survival}},
  language     = {{eng}},
  number       = {{6}},
  publisher    = {{Taylor & Francis}},
  series       = {{Molecular and Cellular Oncology}},
  title        = {{SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery}},
  url          = {{http://dx.doi.org/10.1080/23723556.2020.1805094}},
  doi          = {{10.1080/23723556.2020.1805094}},
  volume       = {{7}},
  year         = {{2020}},
}